Robust, long-lasting immune responses are elicited by memory T cells that possess properties of stem cells, enabling them to persist long-term and to permanently replenish the effector pools. Thus, stem cell-like memory T (T SCM ) cells are of key therapeutic value and efforts are underway to characterize T SCM cells and to identify means for their targeted induction. Here, we show that inhibition of mechanistic/mammalian Target of Rapamycin (mTOR) complex 1 (mTORC1) by rapamycin or the Wnt-β-catenin signalling activator TWS119 in activated human naive T cells leads to the induction of T SCM cells. We show that these compounds switch T cell metabolism to fatty acid oxidation as favoured metabolic programme for T SCM cell generation. Of note, pharmacologically induced T SCM cells possess superior functional features as a long-term repopulation capacity after adoptive transfer. Furthermore, we provide insights into the transcriptome of T SCM cells. Our data identify a mechanism of pharmacological mTORC1 inhibitors, allowing us to confer stemness to human naive T cells which may be significantly relevant for the design of innovative T cell-based cancer immunotherapies.
Introduction
Similar to solid organs, T cells have been suggested to harbour a selfrenewing stem cell-like population which permanently replenishes the pools of further differentiated effectors. Since central memory T (T CM ) cells have been shown to repopulate the effector memory T (T EM ) cell and effector T (T EFF ) cell pools in response to antigen stimulus (Graef et al., 2014; Wherry et al., 2003) , they were thus far regarded as "memory stem cells". However, further complexity was brought to this view by the recent discovery of an additional memory T cell subset, which was able to mediate a prolonged immune response in a mouse model of graft-versus-host disease (GVHD) (Zhang et al., 2005) . This memory T cell subset, termed stem cell-like memory T (T SCM ) cells, has been recently described in mice, non-human primates and in humans (Gattinoni et al., 2009 (Gattinoni et al., , 2011 Lugli et al., 2013) . As least differentiated distinct memory T cell subset, T SCM cells have been put at the top of the hierarchy of all memory T cell subsets in a model of progressive T cell differentiation, leading from naive T (T N ) cells over T SCM cells and T CM cells to T EM cells and T EFF cells. This position of T SCM cells between T N cells and memory T cells is phenotypically reflected by the expression of activation markers as the death receptor CD95, the β-chain of the IL-2 receptor (CD122) or the adhesion molecule CD58 on naiveappearing CCR7 +, CD45RA +, CD45RO − T cells (Gattinoni et al., 2011) . After genetic modification into mesothelioma-specific CAR T cells, adoptively transferred T SCM cells were shown to mediate an improved anti-tumour immune response compared to T N cells, T CM cells and T EM cells in a humanized mouse model (Gattinoni et al., 2011) , which seems to depend on a more efficient T SCM cell engraftment and long-term persistence in the host which enables them, while selfrenewing, to constantly differentiate into T EFF cells and, thereby, to completely eradicate the tumour.
Because of these ideal characteristics there is a quest for the signalling pathways which mediate T SCM cell induction. Once identified, pharmacological interference with these signalling pathways could be used for their targeted induction in anti-tumour immunotherapy. In this regard, the in vitro activation of CD8 + T N cells in the presence of the Wnt-β-catenin (short: Wnt) signalling pathway activator TWS119, which inhibits glycogen synthase kinase-3β (GSK-3β) by phosphorylation, has been suggested to arrest T N cell differentiation and to generate T SCM cells (Gattinoni et al., 2011) . However, the interpretability of these data remains inconclusive, since the starting pool of T N cells also contained T SCM cells so that an expansion effect of TWS119 on preexisting T SCM cells or T SCM cell self-maintaining factors cannot be excluded. Moreover, increasing evidence suggests that T cell metabolism is an important determinant of T cell differentiation (Pearce et al., 2009) , which raises the possibility that metabolic integrators like mechanistic/mammalian Target Of Rapamycin (mTOR) kinase might represent pharmacological targets for the enrichment of a desired differentiation-defined T cell population (Araki et al., 2009; Diken et al., 2013; Rao et al., 2010; Turner et al., 2011) , thereby potentially favouring the induction of qualitatively improved memory T cells.
We, therefore, set out to investigate whether mTORC1 inhibitors like rapamycin would be relevant for the generation of human T SCM cells and whether a cross-talk between mTOR and Wnt signalling would exist. Moreover, since current knowledge on the generation and characterization of T SCM cells remains limited to CD8+ T SCM cells, apart from their phenotypic definition, CD4 + T SCM cells remain uninvestigated. The characterization of CD4 + T SCM cells seems to be of great importance all the more, as the role of CD4+ T cells as broad orchestrators of the immune response receives growing attention in anti-tumour immunotherapy (Kamphorst and Ahmed, 2013; Muranski and Restifo, 2009) . In the present study, therefore, focus was put on the induction and characterization of CD4+ T SCM cells, nevertheless testing the relevance of our findings on T SCM cell induction also for CD8+ T SCM cells.
Here, we revealed the inhibition of mTORC1 with simultaneously active mTORC2 signalling as the molecular mechanism inducing T SCM cells and that T SCM cell induction takes place in complete independence from Wnt signalling. We furthermore present insights into the transcriptomes of naturally occurring and pharmacologically induced CD4+ T SCM cells, the in vivo survival and repopulation capacity of pharmacologically induced CD4+ T SCM cells and the metabolic regulation of CD4+ T SCM cell generation. Taken together, our findings are of direct relevance for the design of improved anti-tumour immunotherapies.
Materials & Methods

Human T Lymphocytes
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation over a Ficoll-Paque gradient (Lymphoprep™) from buffy coats of healthy human female and male blood donors, obtained from the Vaud blood transfusion service. Experiments were performed in accordance to the guidelines of the Ethics Commission of the UNIL. Prior to sorting, PBMCs were purified with CD3, CD4 or CD8 Dynabeads® (Invitrogen™).
Animal Experiments
Animal experiments were performed in accordance to the guidelines of the Ethics Commission of the UNIL. In vitro experiments and assessment of T SCM cell frequencies were performed with female Raptor (CD4-Cre), β-/γ-catenin (Vav-Cre) KO mice and their corresponding WT forms. Adoptive T cell transfer was conducted with female NOD.Cg-Prkdc scid Il2rg tm1WjI /SzJ mice (NSG).
Cell Culture
T cells were cultured in RPMI-1640 supplemented with 8% heat inactivated, pooled human serum or 10% foetal calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin, 4 mM L-glutamine, 1% (v/v) nonessential amino acids and 50 μM 2-mercaptoethanol. Sorted T N cells were primed with anti-CD3/CD28 beads (Invitrogen) or OKT3/anti-CD28 antibody (in house, derived from hybridoma cells) and IL-2 (Proleukin®, Roche Pharma AG). Pathway interfering drugs were TWS119 (Cayman Chemical), rapamycin (LC Laboratories), PP242 (Chemdea), KU-0063794 (Chemdea), Indirubin-3-monoxime (SigmaAldrich), SB216763 (Sigma-Aldrich) and recombinant human Wnt3A (R&D Systems).
Flow Cytometry
Flow cytometry acquisition was performed with a Gallios™ (Beckman Coulter) or a LSR II flow cytometer (BD Biosciences). Cell sorting was conducted with a FACS Aria (BD Biosciences) or a MoFlo® Astrios™ cell sorting instrument (Beckman Coulter). Flow cytometry analysis was performed with FlowJo software (Version 7.6.5, Treestar).
Antibodies and staining panels are listed in the Supplemental Experimental Procedures.
2.5. Phospho-specific Flow Cytometry 1,000,000 T N cells were sorted per condition. After activation with anti-CD3/CD28 beads (1:1 bead/cell ratio) in the presence of TWS119 (5 μM) or rapamycin (100 nM) for 4 h, T N cells were harvested, fixed and incubated with ice-cold 50% methanol for membrane permeabilization. Primary antibodies were pS6 ribosomal protein (Ser235/ 236), pGSK-3β (Ser9), pAKT (Ser473), p4EBP1 (Ser65), p4EBP1 (Thr37/46) (all from Cell Signaling). The secondary antibody was Alexa Fluor 647 goat anti rabbit IgG (Life Technologies).
Western Blot Analysis
For Western blot analysis activated (4 h in presence of indicated drugs) natural (n) CD4 + T N cells were washed in ice-cold PBS and lysed in RIPA buffer containing protease inhibitor and sodium orthovanadate (Santa Cruz Biotechnologies). Proteins were separated by 4% to 12% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Millipore). Membranes were blocked with Odyssey® blocking buffer (LI-COR Biosciences) and immunoblotted with the primary antibodies pS6 ribosomal protein (Ser235/236), pAKT (Ser473), β-actin (all from Cell Signaling) followed by infrared secondary antibodies. Bands from immunoreactive proteins were visualized by an Odyssey® infrared imaging system (LI-COR Biosciences).
RNA Sequencing
RNA sequencing was conducted with nCD4+ T N , T SCM and T CM cells from 4 healthy human donors. Additionally, TWS119-and rapamycininduced T SCM cells were resorted after 14 days of nCD4+ T N cell priming from the same donors. RNA was purified with Arcturus PicoPure RNA Isolation kit (Biosystems/Applied Life Technologies). An amount of 10 ng total RNA was amplified with the SMARTer Ultra Low RNA Kit for Illumina Sequencing (Clontech Laboratories, Inc.) and the Advantage 2 PCR Kit (Clontech Laboratories, Inc.). The cDNA from the amplification reactions was sheared with a Covaris ultrasonicator (Covaris, Inc.) and sequencing libraries were generated with a Truseq DNA kit (Illumina, Inc.). Libraries were sequenced at 100 nucleotides single read mode on an Illumina HiSeq 2000 instrument.
Adoptive T Cell Transfer
Adoptive T cell transfer was conducted by tail vein injection of 200,000 rapamycin-induced CD4 + T SCM cells and equal numbers of CD4+ T N -like and T CM -like cells. Control mice received an equal volume of culture medium. Lymphocytes from lung and liver were isolated by Percoll™ technique.
Cell Proliferation Assay
30,000 rapamycin-induced CD4+ T SCM cells and equal numbers of T N -and T CM -like cells were labelled for 6 days with carboxyfluorescein succinimidyl ester (CFSE, Life Technologies) (final concentration: 0.25 μM) and expanded in presence of IL-2 (50 IU/ml). Dilution of CFSE (488 nm) was assessed by flow cytometry. The proliferation index was calculated with ModFit LT software (Version 3.3.11, Verity Software House, Inc.).
MMP
Assessment of MMP was performed with TMRE -Mitochondrial Membrane Potential Assay Kit (Abcam®). 5,000,000 nCD4 + T cells and equal numbers of T cells derived from nCD4 + T N cells, which have been activated for 14 days in presence of rapamycin (100 nM), were used. T cells were incubated with 100 nM tetramethylrhodamine, ethyl ester (TMRE) for 30 min at 37°C in the water bath. Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 100 μM) was added during acquisition.
2-NBDG Uptake
2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG, Invitrogen) uptake was carried out with 5,000,000 nCD4+ T cells and equal numbers of T cells, derived from nCD4 + T N cells, which have been activated for 14 days in presence of rapamycin (100 nM). T cells were incubated for 15 min at 37°C in glucose-free Krebs-Ringer Hepes buffer (Hepes 50 mM, NaCl 137 mM, KCl 4.7 mM, CaCl 2 1.85 mM, MgSO 4 1.3 mM, BSA 0.1% w/v, pH 7.4). T cells were pelleted, washed and incubated with 100 μM 2-NBDG at 37°C in the water bath prior to measuring fluorescence by flow cytometry.
Assessment of ECAR and OCR
For extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurements we used an XF24 extracellular analyser (Seahorse™ Bioscience). T N (750,000 per well) and T SCM cells (200,000 per well) have been immobilized using CellTak™ agent (BD Biosciences). T cells were kept in non-buffered assay medium (KHB with 25 mM glucose, 1 mM sodium pyruvate, 2 mM glutamine for ECAR assessment or 2.5 mM glucose and 1.5 mM carnitine for OCR measurement) and incubated in a non-CO 2 incubator for 60 min at 37°C prior to analysis. Anti-CD3/CD28 beads, TWS119, rapamycin, oligomycin and palmitate were added prior to or during the analysis at the indicated time points and concentrations. ECAR and OCR were calculated using Seahorse™ Bioscience proprietary software.
Statistical Analysis
Flow Cytometry
Statistical analysis was performed with Prism software (Version 6, GraphPad), using a paired t-test.
RNA Sequencing
The raw sequencing reads were trimmed with Trim Galore! (http:// www.bio-informatics.babra-ham.ac.uk/projects/trim_galore/) (Version 0.3.3), using cutadapt (Version 1.2.1) to remove low-quality bases (quality Phred score cut-off 15) and remaining adaptor sequences. Further information is provided in the Supplemental Experimental Procedures. For all analyses, a p-value (adj.) less than 0.05 was considered as statistically significant and labelled with *, less than 0.01 with **, less than 0.001 with *** and less than 0.0001 with ****.
Results
TWS119 and Rapamycin Induce Phenotypic T SCM Cells
To assess the influence of Wnt and mTOR on human T SCM cell generation, highly purified CD4 + and CD8 + T N cells (natural (n)) were sorted ex vivo (Fig. S1a) and activated with anti-CD3/CD28 beads (1:1 bead/cell ratio) and IL-2 (300 IU/ml) in the presence of the Wnt activator TWS119 (5 μM) or the mTOR inhibitor rapamycin (100 nM).
After 14 days, nCD4+ T N cells, primed in the presence of TWS119 or rapamycin, formed two lymphocyte populations, a small-sized and a large-sized one, based on forward scatter/side scatter (FSC/SSC) profiles. In contrast, nCD4+ T N cells which have been cultured in the absence of TWS119 or rapamycin did not generate the small-sized lymphocyte population (Fig. 1a) . Phenotypic analysis revealed that the small-sized lymphocyte population mainly consists of T cells with a CCR7 +, CD45RA + T N -like phenotype and a small fraction of cells with a CCR7+, CD45RA-T CM -like phenotype. Of note, the T N -like population displayed phenotypic CD95+, CD58+ T SCM cells which were significantly increased in absolute cell numbers in comparison to T CM -like cells (Fig. 1b, Fig. S1b and Table 1 ), suggesting TWS119 and rapamycin as specific inducers of T SCM cells. These cells co-expressed high levels of the CD62L selectin (not shown). We then subdivided the T N -like population into a CCR7+, CD45RA
intermediate "transition zone" (TZ) and a CCR7 +, CD45RA high "rand zone" (RZ) to investigate whether T SCM cells would be preferentially located in a distinct region of the T N -like population. Interestingly, this was indeed the case, since the TZ contains higher frequencies of phenotypic T SCM cells compared to the RZ ( (Table S1 ), suggesting the small-sized lymphocyte population as place of CD4+ T SCM cell induction.
To further explore the mechanism of T SCM cell induction by TWS119 and rapamycin, we next tested the alternative Wnt activators Indirubin-3-monoxime (4 μM) and Wnt3A (10 nM) as well as the ATPcompetitive mTOR inhibitors PP242 and KU-0063794. PP242 and KU-0063794 used at low concentrations (100 nM) inhibit mTORC1, while at higher concentrations (1 μM) they also block mTORC2 (data not shown). Supporting our finding with rapamycin, 14 days of nCD4 + T N cell priming in the presence of low-concentrations (100 nM) PP242 or KU-0063794 also triggered the formation of a small-sized lymphocyte population with phenotypic T SCM cells ( Fig. 1c and Fig. S1d ). However, surprisingly in contrast to TWS119, the alternative Wnt activators Indirubin-3-monoxime and Wnt3A did not generate a small-sized lymphocyte population (Fig. 1c) , questioning an involvement of Wnt signalling in T SCM cell induction.
Testing these observations for CD8+ T SCM cell induction, priming of highly purified nCD8+ T N cells for 14 days in the presence of TWS119 or rapamycin, in comparison to drug absence or priming in the presence of Indirubin-3-monoxime (4 μM), resulted in increased frequencies of T Nlike cells, displaying a population of phenotypic CD95+, CD58+ T SCM cells (Fig. S1c) , suggesting a common pharmacological mechanism of rapamycin and TWS119 also for CD8 + T SCM cell induction. Thus, taken together, inhibitors of mTOR induce phenotypic CD4 + and CD8 + T SCM cells, whereas, apart from TWS119, other Wnt activating drugs fail in doing so.
TWS119 Inhibits mTORC1
To test the hypothesis about a common pharmacological mechanism of TWS119 and rapamycin in T SCM cell induction, the phosphorylation of GSK-3β (pGSK-3β, read-out for Wnt activity) and the phosphorylation of S6 ribosomal protein (pS6, read-out for mTORC1 activity) were (c) Activation of highly purified human nCD4 + T N cells for 14 days in the presence of PP242 (100 nM) or KU-0063794 (100 nM) also leads to the formation of the small-sized lymphocyte population (red arrows), containing phenotypic CD95+, CD58+ T SCM cells (shown in the total T N -like cell population). In contrast, priming in the presence of the alternative Wnt activators Indirubin-3-monoxime (I-3-M, 4 μM) or Wnt3A (10 nM) does not lead to the formation of the small-sized lymphocyte population (red arrows). n = 4. T SCM = pharmacologically induced phenotypic T SCM cells.
assessed by flow cytometry in highly purified human nCD4+ T N cells (Fig. 2a) and nCD8+ T N cells (Fig. 2b) as well as by Western blot analysis for pS6 in highly purified human nCD4+ T N cells (Fig. 2c ) upon activation and drug interference.
Surprisingly, the Wnt activator TWS119, which was able to induce phenotypic T SCM cells, also abolished the phosphorylation of S6 (Fig. 2a to c) , suggesting an inhibitory effect of TWS119 on mTORC1. Interestingly, whereas the drugs which inhibited mTORC1 (decrease of S6 phosphorylation) were also capable to induce phenotypic T SCM cells, the drugs which activated Wnt (increase of pGSK-3β) did not induce phenotypic T SCM cells, suggesting that phenotypic T SCM cell induction is mediated by inhibition of mTORC1. In line with reports on differential effects on S6 and 4EBP1 (Choo et al., 2008) , TWS119 and rapamycin had no significant effects on p4EBP1, another protein downstream of mTORC1, in nCD4 + T N cells (Fig. S2a ) and nCD8+ T N cells (Fig. S2b) . Moreover, our results suggest that both TWS119 and rapamycin are exerting a mild, suboptimal effect on mTORC1 inhibition (S6K is blocked but 4EBP1 is preserved, as is also mTORC2). Previous studies have demonstrated that S6K is a more sensitive target of mTOR blockade than 4EBP1 (Chresta et al., 2010; Feldman et al., 2009 ). Thus, inhibition of mTORC1 via decrease of S6 phosphorylation and independence from Wnt signalling emerge as the molecular mechanisms which underlie T SCM cell induction.
TWS119 Induces a Differentiation Arrest Independently From Wnt Signalling
To confirm this conclusion on a genetic base, we took advantage of highly purified nCD4+ T N cells from mice with a haematopoietic deletion of β-and γ-catenin, resulting in abolished Wnt signalling. In mice, T SCM cells were phenotypically defined by the expression of Sca-1 (Ly6A/E) and CXC chemokine receptor 3 (CXCR3) on naive-appearing CD44−, CD62L+ T cells (Fig. S3a) (Gattinoni et al., 2009; Zhang et al., 2005) . Since mouse nCD4 + T N cells did not tolerate long drug treatment phases, we needed to reduce priming periods to 4 days with 1.5 μM TWS119, an interval possibly too short to trigger an upregulation of T SCM cell markers. However, to confirm its independence from Wnt signalling, we hypothesised that under these conditions TWS119 would at least arrest a fraction of activated β-and γ-catenin KO nCD4 + T N cells in a T N -like state, in analogy to the formation of the small-sized lymphocyte population observed in the in vitro experiments with human nCD4+ T N cells. Interestingly, as observed for the mTORC1 inhibitor rapamycin, this was also indeed the case for TWS119, whereas the alternative Wnt activator SB216763 (2 μM), which does not inhibit mTORC1, failed in doing so (Fig. 3 and Fig. 2c) . Thus, these data further confirm that the mediation of a differentiation arrest, as prerequisite for T SCM cell induction, is independent from Wnt signalling, but dependent on mTORC1 inhibition. To further corroborate these findings, we then assessed T SCM cell levels in the spleens of β-and γ-catenin KO mice, using the above mentioned phenotype. Suggesting no impairment in T SCM cell generation in the absence of Wnt signalling, β-and γ-catenin KO mice exhibited naturally occurring T SCM cells in comparable frequencies as their WT counterparts (Fig. S3b) . Furthermore, we took advantage of mice with a T cellspecific KO of the mTORC1 regulatory component Raptor, which leads to an abolishment of mTORC1 signalling. Interestingly, supporting our in vitro findings of rapamycin-mediated T SCM cell induction, we found significantly increased T SCM cell frequencies in these mice (Fig. S3c  and Fig. S3d) . Moreover, excluding an off-target effect of rapamycin, additional treatment of Raptor KO nCD4+ T N cells during 4-day priming with rapamycin (100 nM) did not result in an increased fraction of cells in a T N -like state (Fig. S3e) . Altogether, these data present further evidence for the inhibition of mTORC1 as the molecular mechanism underlying T SCM cell induction.
Transcriptome Analysis of Naturally Occurring and Pharmacologically Induced T SCM Cells
By transcriptome analysis, we next set out to assess the degree of relatedness between naturally occurring CD4+ T N , T SCM and T CM cells as well as TWS119-and rapamycin-induced CD4 + T SCM cells to gain insights into distinct profiles of gene expression in CD4 + T SCM cells. In naturally occurring T cell subsets, unsupervised analysis showed a very close relatedness between T SCM and T CM cells compared to T N cells ( Fig. 4a and b) , potentially indicating a continuous transition from T SCM to T CM cells during differentiation. Suggesting CD4+ T cell differentiation as process which may be strictly regulated by a core set of genes, only 895 genes were found to be significantly differentially expressed between T N and T SCM cells and 141 genes between T SCM and T CM cells by supervised analysis (adj. p b 0.05; | log2FC | N 1) (Fig. 4c , Table S2, Table S3 ). To identify further differences between T SCM and T CM cells with respect to the stem cell-like nature of T SCM cells, we carried out a gene set enrichment analysis for stem cell characteristic genes (view Supplemental Information) and could identify FGFR1, RB1 and NOTCH2 to be highly expressed in T SCM cells in comparison to T CM cells (adj. p = 0.07). Of further interest for the distinction of T SCM from T CM cells, 18 genes were found to be significantly differentially expressed between these otherwise closely related subsets and not shared by any other subset ( Fig. 4c and Table 4 ). In addition, a set of 56 genes could be identified to be significantly differentially expressed between T N and T SCM cells and between T SCM and T CM cells, thus, showing a unique expression profile in T SCM cells (Fig. 4c and Table 2 ). Interestingly, from these 56 genes only 4 genes, SLC22A17, RAI2, SALL2 and LOC338651, were down-regulated in T SCM cells (Fig. S4a) , whereas all the other genes were up-regulated. Moreover, with exception of TCF4, Wnt signalling transducers could be found to be highly expressed either in both, T N and T SCM , or significantly up-regulated in T N cells, further arguing against the theory that activation of the Wnt pathway in T N cells induces T SCM cells (Fig. S4b) .
Interestingly, TWS119-and rapamycin-induced T SCM cells showed a very close degree of relatedness. From 21,481 interrogated genes, only 565 genes were significantly differentially expressed between them (adj. p b 0.05; |log2FC| N 1), further supporting our finding of a common pharmacological mechanism of these drugs (Fig. 4a to c and Table S5 ). However, since TWS119-and rapamycin-induced T SCM cells have received strong activating stimuli over 14 days, it was likely that their transcriptome differed from the ones of naturally occurring T SCM cells, directly sorted ex vivo in their resting state. Nonetheless, we hypothesised that the set of well-known factors of human effector and memory T cell differentiation would show a comparable expression profile in naturally occurring and pharmacologically induced T SCM cells (Gattinoni et al., 2011) . Indeed, similar expression levels of the regulators of effector differentiation CXCR3, KLRG1, PRDM1 and TBX21 could be found (Fig. 4d) . Interestingly, in vitro induced T SCM cells exhibited higher expression levels of GZMA and PRF1 (Fig. 4d) , probably equipping them with superior direct effector functions. In vitro induced and naturally occurring T SCM cells displayed a similar expression level of TNF, but, notably, in vitro induced T SCM cells exhibited low IFNG expression levels (Fig. S4c) . This might be a result of IFNG down-regulation due to mTORC1 inhibition, a mechanism described for type I interferons in plasmacytoid dendritic cells mediated by interferon-regulatory factor (IRF) 7 (Cao et al., 2008) . Interestingly, IRFs are involved in CD4 + T cell differentiation (Lohoff and Mak, 2005) , and IRF7 was found to be up-regulated in in vitro induced T SCM cells (Fig. S4c) . Furthermore, similar expression levels of the inhibitory factors for T cell activation and differentiation CERS6, EOMES, LEF1, TAF4B and ACTN1 as well as for the T SCM cell characteristic factors CD27, ITGAL, IL2RB and TNFSF9 could be identified (Fig. 4d) . In addition, the expression levels of genes encoding distinct interleukins are shown in Fig. S4d . Finally, confirming the purity of the performed cell sorts, naturally occurring T N , T SCM and in vitro induced T SCM cells expressed similarly low amounts of HNRPLL, a key regulator of the alternative splicing of the CD45 pre-mRNA (Oberdoerffer et al., 2008) . Additionally, FAS was among the most significantly differentially expressed genes between naturally occurring T N and T SCM cells (Fig. S4e) . Altogether, these data present insights into the transcriptional regulation of T SCM cells and underline the pharmacological inhibition of mTORC1 as a molecular mechanism to confer stemness to a population of activated T N cells.
In Vitro Induced T SCM Cells Exhibit a Long-term Repopulation Capacity in Vivo
The distinct up-regulation of transcripts encoding telomerase, antiapoptotic genes and positive cell cycle regulators and down-regulation of pro-apoptotic genes and CDK inhibitors ( CD4+ T SCM cells might exhibit a superior in vivo long-term persistence. We directly assessed this potential in vivo long-term persistence by adoptive transfer of 200,000 rapamycin-induced CD4+ T SCM cells, isolated to high purity by flow cytometry-based cell sorting, into NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. Ten weeks after adoptive transfer, peripheral blood, spleen, bone marrow, lung and liver were investigated by multicolour flow cytometry for T SCM cell persistence ( Fig. 5a and Fig. S5b) . Interestingly, in two of three experiments, the spleens of the mice, which have received T SCM cells, showed the presence of a live CD3+, CD4+ T cell population with a CCR7−, CD45RA-intermediate phenotype (Fig. 5a ), indicating both, the potential of in vitro induced CD4+ T SCM cells to persist long-term in vivo and their ability to repopulate the effector pools by giving rise to further differentiated progeny. In a third experiment, adoptively transferred T SCM cells yielded live CD3+, CD4+ T cells in the peripheral blood ten weeks after adoptive transfer (Fig. 5a) . In contrast, no T cells could be detected after adoptive transfer of same numbers of T N -like or T CM -like cells, resorted from the small-sized lymphocyte population from the same in vitro cell culture (Fig. S5b) . Spleen size and weight did not exhibit any differences between the groups (Fig. S5b) . Of note, compared to naturally occurring CD4 + T N cells, in vitro induced CD4 + T SCM cells showed an up-regulation of the haematopoietic stem cell engraftment genes HOXA1 and LPXN (Powers and Trobridge, 2013) , which might have mediated their superior engraftment capacity (Fig. S5c) . Together, these data suggest a potential advantage of pharmacologically induced CD4 + T SCM cells in mediating a prolonged immune response after adoptive transfer. Of note, we did not observe signs of xeno-GVHD in contrast to a report showing that rapamycin-treated T cells caused more xeno-GVHD (Amarnath et al., 2010) . Further studies are warranted to assess the relative functional features of rapamycin-induced T SCM cells and their long-term repopulation capacity after adoptive transfer.
Next, the proliferative capacity of 30,000 rapamycin-induced CD4+ T SCM cells in comparison to equal numbers of T N -like and T CM -like cells, re-sorted from the small-sized lymphocyte population from the same in vitro cell culture, was assessed by CFSE dilution assay. T cells were either left for 6 days in presence of IL-2 (50 IU/ml) or, additionally, stimulated with OKT3 (1 μg/ml) and anti-CD28 antibody (10 μg/ml) (Fig. 5b) . Interestingly, in two of six experiments, stimulated in vitro induced T SCM cells formed a small-sized resting T cell population in addition to a large proliferating one, probably reflecting their stem cell nature, which is both, the capacity to self-renew and to differentiate (Fig. 5b) .
Substrate Utilization and Cellular Metabolism of T SCM Cells
Increasing evidence suggests that T cell differentiation is controlled by fine-tuned modulations of glycolysis and fatty acid oxidation (FAO) (Cham et al., 2008; Fox et al., 2005; Zheng et al., 2009) . To investigate the predominance of a distinct metabolic programme in T SCM cells, we next measured the uptake capacity of the fluorescent glucose analogue vav-cre, bottom) nCD4+ T N cells after 4 days of in vitro activation with anti-CD3 (2 μg/ml), anti-CD28 antibody (2 μg/ml) and IL-2 (10 ng/ml). In contrast, SB216763 (2 μM) fails to mediate this differentiation arrest in activated WT and KO nCD4+ T N cells. T N -like cell frequencies are depicted as percentages of live CD3+, CD4+ T cells. n = 3. Data are represented as mean ± SEM. ns = not significant.
2-NBDG in rapamycin-induced T SCM cells in comparison to T N -like, T CMlike and T EM -like cells and to the respective naturally occurring T cell subsets as reference point for glycolytic activity (Sukumar et al., 2013b) . Interestingly, compared to the divergent glucose uptake of T EM cells and T EM -like cells, all other T cell subsets exhibited a limited glucose uptake, suggesting especially for T SCM cells an independence from glycolysis (Fig. 5c) . In line, pharmacologically induced T SCM cells also showed low expression of the gene encoding the master regulator of glycolytic enzyme HIFA (Fig. S5d) . Alternatively, as reference point for oxidative metabolism such as FAO, we measured the mitochondrial membrane potential (MMP) in the mentioned T cell subsets by assessment of their uptake of TMRE, a dye, which accumulates in active mitochondria of short-lived effectors (Sukumar et al., 2013a) . Accordingly, we could find an increase of TMRE uptake going along with progressive cellular differentiation (Fig. 5d) .
Since these observations suggest that T SCM cells rather gain their energy from an oxidative metabolism, we hypothesised that FAO might also be the relevant metabolic programme in the induction of T SCM cells. We, therefore, investigated the impact of the pharmacological T SCM cell inducers TWS119 and rapamycin on the metabolism of activated nCD4+ T N cells by assessment of ECAR, which is an indicator of glycolytic activity, and OCR, which is an indicator of mitochondrial respiration, by Seahorse analysis (Fig. 5e left) . Interestingly, administration of TWS119 (5 μM) or rapamycin (100 nM) prevented the development of full cellular glycolytic activity in response to oligomycin (1 μg/ ml), a drug, enforcing maximal glycolysis. Thus, we hypothesised that TWS119 and rapamycin initiate a metabolic programme for T SCM cell induction which is alternative to glycolysis. To disclose whether this metabolic programme would be FAO, we triggered mitochondrial respiration in rapamycin-pretreated (100 nM, 2 h) and activated nCD4+ T N cells by administration of palmitate (500 μM), the ester of retinol and palmitic acid. Interestingly, the presence of palmitate increased mitochondrial respiration to the levels measured in nCD4 + T SCM cells (Fig. 5e right) . Thus, these data present evidence for FAO as metabolic programme characteristic of T SCM cells and needed for T SCM cell induction.
Discussion
The identification of the signalling pathways, underlying T SCM cell formation, allows their targeted induction and paves the way for the design of novel immunotherapeutic approaches. Here, we show the emergence of a T cell population with phenotypic, transcriptional, functional and metabolic hallmarks of naturally occurring T SCM cells upon in vitro inhibition of mTORC1 during priming of human T N cells. These findings emphasize the potential relevance of the signalling network of mTOR kinase in immunotherapy and of mTOR modulating pharmacological agents.
Interestingly, we show that mTORC1 inhibition with drugs like rapamycin mediates an immunostimulatory effect by the induction of T SCM cells, although these drugs are generally used because of their immunosuppressive function (Cobbold, 2013; Ferrer et al., 2011) . Thus, these observations indicate that there are distinct conditions which trigger either a preferential immunostimulatory or an immunosuppressive rapamycin effect. Among a variety of different molecular mechanisms, rapamycin has been suggested to fulfil its immunosuppressive function by prevention of full T cell activation (Loewith et al., 2002; Thomson et al., 2009 ). This effect can be circumvented by strong stimulation of the TCR and co-stimulatory receptors (Slavik et al., 2004) . Similarly, in the in vitro experiments the high degree of activation of T N cells by anti-CD3/CD28 beads in a 1:1 bead/cell ratio and 300 IU/ml IL-2 might have favoured an immunostimulatory rapamycin effect. Furthermore, rapamycin has been shown to increase the antigen-specific T cell response to a pathogen (short-term persistence of the antigen), but to fail in doing so in response to a graft (long-term persistence of the antigen) (Ferrer et al., 2010) . These findings strongly suggest that the period of antigen persistence also regulates the immunological outcome of rapamycin. Thus, the rather short periods of T N cell activation (14 days and 4 days) in our in vitro experiments might have tipped the balance towards an immunostimulatory rapamycin effect. The used concentration of rapamycin also emerges as an important factor for mediating either an immunostimulatory or an immunosuppressive drug effect. For the in vitro induction of T SCM cells, rapamycin was used in 100 nM (90 ng/ml), since a rather high concentration of 40-100 ng/ml rapamycin, administered during the contraction phase, has been shown to qualitatively improve antigen-specific memory T cells in a mouse model of CD8 + T cell response to acute viral infection (Araki et al., 2009) . In contrast, 8-12 ng/ml rapamycin blood levels are intended to induce immunosuppression after transplantation (Baan et al., 2005) . Together, this suggests that a low rapamycin concentration preferentially results in an immunosuppressive effect, whereas a high rapamycin concentration triggers an immunostimulatory one. Also the immunomodulatory actions of rapamycin might be regulated by the interplay between the two mTOR complexes. Whereas T SCM cell induction, as shown here, follows mTORC1 inhibition without additional inhibition of mTORC2, formation of immunosuppressive regulatory T cells is favoured in additional absence of mTORC2 signalling (Chi, 2012) . Thus, immunomodulation by rapamycin appears to be a finetuned, highly multidimensional process.
Furthermore, we show that the induction of T SCM cells is completely independent from the Wnt signalling pathway. In line with this, the role of Wnt in memory T cell formation has already been called into question by reports about memory T cell formation in CD8+ T cells, in which β-catenin was conditionally knocked out (Driessens et al., 2010; Prlic and Bevan, 2011) . Nevertheless, these reports have to be seen with caution, since, in contrast to our study, specifically, T SCM cell formation was not investigated and mice with KO of only β-catenin, which might have favoured a bypassed activity of Wnt signalling by γ-catenin, were used. Moreover, our data offer an unexpected answer to the paradox finding that the Wnt activator TWS119 induces T SCM cells, whereas none of alternative Wnt activators was able to do so, by the discovery of an mTORC1 inhibiting effect of TWS119. Interestingly, this effect finds further confirmation by a recent report, confirming in mouse T cells that TWS119 inhibits mTORC1 (Xiao et al., 2013) . At present, it is unclear what the scope of TWS119 off-target effects on other kinases is or whether its inhibition of the mTORC1 kinase requires, as rapamycin, FKBP12. Future biochemical and pharmacological studies will have to address the precise molecular mechanism of mTORC1 inhibition by TWS119.
We also showed that mTORC1 inhibition switched the metabolic programme of activated nCD4+ T N cells to an oxidative metabolism dependent on FAO. However, prominently, in the in vitro experiments only a fraction of activated T N cells was arrested in a T N -like state by TWS119 or rapamycin, suggesting that not all T N cells from the phenotypically homogenous CCR7+, CD45RA+ starting population react to mTORC1 inhibition in the same way. Future studies will have to address whether T N cell intrinsic factors can be identified which predispose certain cells to stop differentiation upon mTORC1 inhibition. One such factor might be Krüppel-like-factor 2 (KLF2) which has been shown to maintain the expression of CCR7 and CD62L and has been suggested to be upregulated upon mTORC1 inhibition (Chi, 2012; van der Windt et al., 2012) . Interestingly, only a small fraction of the CCR7 +, CD45RA +, nCD4+ T N cell starting pool exhibited a high KLF2 expression, whereas the vast majority showed a low expression of KLF2 (Fig. S5e) , suggesting KLF2 as possible discriminator to delineate T N cells with T SCM cell precursor potential.
We sought to compare the transcriptome of CD4 + T SCM cells induced by either TWS119 or rapamycin. Indeed, we observed a very highly overlapping gene expression signature shared by rapamycinand TWS119-induced CD4 + T SCM cells. Among 21,481 interrogated genes, only 565 genes were significantly differentially expressed between them (adj. p b 0.05; |log2FC| N 1), further supporting a common pharmacological mechanism of these drugs. It is very interesting that several of the up-regulated genes in the rapamycin treatment group were related with cell metabolism (Supplemental Table 5 ). Of note, the most highly up-regulated gene with rapamycin induction is NAD(P)H:quinone oxidoreductase (NQO1), which protects cells against oxidative stress and toxic quinones. In line with this, TXNRD1 (encoding the thioredoxin reductase 1) was also up-regulated in rapamycininduced T SCM cells. This protein could reduce thioredoxins and plays an important role in protection against oxidative stress. High expression of NQO1 and TXNRD1 might be closely related with the increased oxidative phosphorylation and fatty acid oxidation upon rapamycin induction of T SCM , which definitely needs to be addressed further. On the other hand, the most up-regulated gene in TWS119-induced T SCM cells is LAMP3 (CD63). CD63 is barely expressed in naïve T cells but induced upon T cell activation. Crosslinking of CD63 has been shown to deliver a potent co-stimulatory signal to T cells. To our surprise, we noticed a striking induction of interferon responsive gene expression pattern in TWS119-induced T SCM cells (for example, interferon-induced protein with tetratricopeptide repeats 2, IFIT2; Interferon-Induced Protein with Tetratricopeptide Repeats 3, IFIT3; interferon alpha-inducible proteins 6, IFI6; interferon alpha-inducible proteins 27, IFI27). Many of these genes have been shown to be important for antiviral innate immunity. Some of them emerge to play important roles in regulating T cell activation and immune response. For instance, ISG15 protease UBP43 (USP18) regulates T cell activation. USP18 deficient T cells exhibit hyperactivation of NF-κB and NFAT upon TCR triggering and are defective in Th17 differentiation. The roles of many of those genes in regulating T cells immunity remain to be determined in the near future.
From a translational standpoint, T SCM cells emerge as most promising population for immunotherapy. In this regard, recent reports which indicate that the efficacy of CAR T cells might be based on their acquisition of a T SCM cell phenotype are highly encouraging (Yang et al., 2014) ; however, previous work showed that also other T cell populations have the capacity to persist long-term in vivo (Berger et al., 2008; Markley and Sadelain, 2010) . Our data suggest the use of rapamycin for efficient in vitro T SCM cell induction or in vivo application to enrich for antigen-specific T SCM cells, which should be performed over a short period and by high drug concentration. However, the latter approach will need clinical studies titrating rapamycin doses and assessing different application time-points. Also our insights into T SCM cell metabolism could be used for clinical purposes, since it seems to be rational to provide glucose in treatment phases in which a strong immune attack by T EFF cells is desired. In contrast, in periods of long-term tumour control, in which T cells should enter low differentiation states, substrates allowing FAO should be unrestrictedly provided. In addition, future studies will have to assess the characteristics of and interplay between naturally occurring CD8+ T SCM cells and CD4+ T SCM cells as well as their rapamycin-and TWS119-induced counterparts in preclinical and clinical in vivo settings.
Thus, cellular signalling and metabolism emerge as most promising targets to influence T SCM cell differentiation for the design of innovative immunotherapies.
